Hoth Therapeutics Inc (HOTH) Actualités

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients...

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular...

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and...

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Jan. 24, 2025 NEW...

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications PR...

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 PR Newswire NEW YORK, Jan. 17, 2025...

Form 4 - Statement of changes in beneficial ownership of securities

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries PR Newswire NEW YORK, Jan. 8, 2025 The...

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer...

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment PR...

Form 8-K - Current report